NEW YORK (GenomeWeb News) – Nasdaq announced that it has completed its semi-annual ranking of the Nasdaq Biotechnology Index, and as a result Celera will be added to the index as of the opening of trade on Nov. 24.
While Celera was added, Decode Genetics and Orchid Cellmark have been dropped from the index.
The Nasdaq Biotech Index is ranked on a semi-annual basis in May and September. Firms must meet certain classification criteria and must be listed on the Nasdaq Global Market or Nasdaq Global Select Market. They also must meet minimum requirements for market value, average daily share volume, and seasoning as a public company.